neratinib: Clinical Trials

37 trials of neratinib, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

25 completed, 5 terminated, 2 active not recruiting, 2 recruiting. 37 Phase 1, 12 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 137Completed 25, Terminated 5, Active not recruiting 2, Recruiting 2, Withdrawn 2, Suspended 1
Phase 212Completed 7, Terminated 2, Active not recruiting 1, Suspended 1, Withdrawn 1

Follow neratinib: new trials by email Literature Review of neratinib trials Research Report on neratinib

Trials (filtered) newest first · largest first

All 37 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene
Biopsy Procedure, Biospecimen Collection, Computed Tomography - Metastatic Malignant Solid Neoplasm, Metastatic Pancreatic Adenocarcinoma
Phase 1RecruitingNational Cancer Institute (NCI)582022-10-052026-11-12
Neratinib and Capmatinib Combination (Phase Ib/II) in Metastatic Breast Cancer and Inflammatory Breast Cancer Patients With Abnormal HER-family and c-Met Pathway Activity as Measured by the CELsignia Signaling Analysis Test
Neratinib, Capmatinib - Metastatic Breast Cancer, Breast Cancer
Phase 1 / Phase 2TerminatedM.D. Anderson Cancer Center102022-08-182025-06-11
Neratinib and Fam-Trastuzumab Deruxtecan in Advanced Gastro-esophageal Cancer Patients
Neratinib Pill, Fam-Trastuzumab Deruxtecan-Nxki (TDxD) - Gastric Cancer, Gastrointestinal Cancer
Phase 1RecruitingFox Chase Cancer Center182022-06-242026-09-21
Niraparib and Neratinib in Advanced Solid Tumors With Expansion Cohort in Advanced Ovarian Cancer
Neratinib 160 mg, Neratinib 200 mg, Neratinib 240 mg - Advanced Solid Tumor, Ovarian Cancer
Phase 1Active not recruitingVirginia Commonwealth University182020-08-242026-05-11
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
Abemaciclib, Abiraterone, Afatinib - Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Anatomic Stage IV Breast Cancer AJCC v8
Phase 1TerminatedOHSU Knight Cancer Institute22020-04-012024-03-04
Neratinib + Valproate in Advanced Solid Tumors, w/Expansion Cohort in Ras-Mutated Ca
Neratinib, Divalproex Sodium - Solid Tumor, Adult
Phase 1 / Phase 2SuspendedVirginia Commonwealth University802019-05-012026-10-21
Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Breast Cancer
Cyclophosphamide, Doxorubicin, Laboratory Biomarker Analysis - Breast Inflammatory Carcinoma, Locally Advanced Breast Carcinoma
Phase 1 / Phase 2TerminatedM.D. Anderson Cancer Center342018-02-192026-02-12
Capecitabine 7/7 Schedule With Neratinib in Patients With Metastatic HER2-Positive Breast Cancer
Capecitabine, Neratinib, EORTC QLQ - BR23, EQ-5D-5L, EORTC QLQ-C30 - Breast Cancer
Phase 1 / Phase 2CompletedMemorial Sloan Kettering Cancer Center342017-12-132026-10-16
Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation
Everolimus, Neratinib, Palbociclib - Advanced Malignant Solid Neoplasm, EGFR Gene Amplification
Phase 1TerminatedM.D. Anderson Cancer Center842017-10-312026-07-22
Safety and Dose Finding Study of Neratinib in Children and Young Adults With Cancer That Has Returned or Not Responded to Treatment
Neratinib - Solid Tumor, Central Nervous System Tumor
Phase 1 / Phase 2Active not recruitingMemorial Sloan Kettering Cancer Center142016-10-012026-11-04
Phase1 of Neratinib+Trastuzumab, Pertuzumab, Paclitaxel in Patients With Advanced Solid Tumors/HER2+
Neratinib, Paclitaxel, Pertuzumab - Solid Tumor
Phase 1TerminatedMichelle Melisko62015-11-032017-11-17
A Dose-Escalation Study Evaluating the Combination of Trastuzumab Emtansine (T-DM1) With Neratinib in Women With Metastatic HER2-Positive Breast Cancer
Neratinib, T-DM1 - Breast Cancer
Phase 1 / Phase 2CompletedNSABP Foundation Inc492014-08-012023-01-26
Open-label PK Study to Evaluate Lansoprazole and Neratinib in Healthy Subjects
Lansoprazole, Neratinib - Healthy
Phase 1CompletedPuma Biotechnology, Inc.152014-08-012016-05-11
Safety and Efficacy Study of Neratinib and Cetuximab to Treat Patients With Quadruple Wild-Type Metastatic Colorectal Cancer
Cetuximab, Neratinib - Colorectal Cancer
Phase 1 / Phase 2WithdrawnNSABP Foundation Inc2013-10-012021-10-27
Study Evaluating The Effect Of A High-Fat Meal On The Pharmacokinetics Of Neratinib
Neratinib - Healthy
Phase 1WithdrawnPuma Biotechnology, Inc.2012-08-012012-05-14
Combination of Weekly Paclitaxel With Neratinib and Trastuzumab in Women With Metastatic HER2-positive Breast Cancer
Paclitaxel, trastuzumab, Neratinib - Breast Cancer
Phase 1CompletedNSABP Foundation Inc212011-05-012014-07-08
Temsirolimus Plus Neratinib for Patients With Metastatic HER2-Amplified or Triple Negative Breast Cancer
Temsirolimus, Neratinib - Breast Cancer
Phase 1 / Phase 2CompletedPuma Biotechnology, Inc.992010-04-012018-09-26
A Study Of Neratinib (HKI-272) And Capecitabine In Japanese With Solid Tumor
Neratinib, Capecitabine - Advanced Malignant Solid Tumors
Phase 1CompletedPuma Biotechnology, Inc.72010-04-012018-12-19
Study Evaluating Neratinib In Combination With Vinorelbine In Subjects With Advanced Or Metastatic Solid Tumors
Neratinib, Vinorelbine - Advanced Malignant Solid Tumors
Phase 1CompletedPuma Biotechnology, Inc.62009-07-012018-06-28
Study Evaluating The Potential Effect Of Rifampin On The Pharmacokinetics Of Neratinib
Neratinib - Healthy Subjects
Phase 1CompletedPuma Biotechnology, Inc.242009-04-012012-05-14

Showing 20 of 37. Sign in to see all of them.

Conditions studied

Breast Neoplasms (14)  ·  Neoplasm Metastasis (4)  ·  Neoplasms (4)  ·  Pancreatic Neoplasms (3)  ·  Anemia (1)  ·  Blast Crisis (1)  ·  Central Nervous System Neoplasms (1)  ·  Colonic Neoplasms (1)  ·  Colorectal Neoplasms (1)  ·  Disease (1)  ·  Disease Progression (1)  ·  Gastrointestinal Neoplasms (1)  ·  Hematologic Neoplasms (1)  ·  Hepatic Insufficiency (1)  ·  Hereditary Sensory and Autonomic Neuropathies (1)

Sponsors

Puma Biotechnology, Inc. (23)  ·  M.D. Anderson Cancer Center (3)  ·  NSABP Foundation Inc (3)  ·  Memorial Sloan Kettering Cancer Center (2)  ·  Virginia Commonwealth University (2)  ·  Fox Chase Cancer Center (1)  ·  Michelle Melisko (1)  ·  National Cancer Institute (NCI) (1)  ·  OHSU Knight Cancer Institute (1)

Countries

United States (29)  ·  China (4)  ·  France (4)  ·  Hong Kong (4)  ·  Japan (4)  ·  Spain (3)  ·  Belgium (2)  ·  Canada (2)  ·  Poland (2)  ·  Russia (2)  ·  South Korea (2)  ·  United Kingdom (2)  ·  Australia (1)  ·  Brazil (1)  ·  Croatia (1)

Top investigators

Norman Wolmark, MD (3)  ·  Andrew Poklepovic, MD (2)  ·  Andrew Davis (1)  ·  Chau Dang, MD (1)  ·  Lara Davis, MD (1)  ·  Namrata Vijavergia, MD (1)  ·  Puma Biotechnology (1)  ·  Rachel Layman (1)  ·  Rachel Layman, MD (1)  ·  Sarina A Piha-Paul (1)  ·  Tanya Trippett, MD (1)

Results publications

PMID 22371427, PMID 22967996, PMID 23632474, PMID 24077916, PMID 24323026, PMID 25287822, PMID 31442103, PMID 33203645, PMID 34482636, PMID 37314501, PMID 37597578, PMID 38650031, PMID 39863139, PMID 41116969

NIH funding

UM1CA186689 (1)